Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia
2018-004802-24Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydrocortisone in 21-hydroxylase deficiency (21-OHD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Salivary 17-hydroxyprogesterone levels and Salivary androstenedione levels. Started May 2019; status: completed.
02
Drugs
hydrocortisone
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2018-004802-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004802-24.